Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 04 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.